Vicor Technologies (VCRT.OB) Adds New Director of Sports Medicine Position to Ever-Growing Team
Those that have followed the strategic corporate developments of Vicor Technologies should now be seeing a consistent theme of systematic growth moves and strategic additions to the executive team. The junior biotech is transitioning smoothly from a developmental company into a revenue-generating organization. Vicor is currently in the process of commercializing diagnostics that enable physicians to accurately risk stratify specific target populations for future pathological events, including cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, diabetics for the presence of diabetic autonomic neuropathy (DAN), and trauma victims for imminent death absent immediate lifesaving intervention. Today, Vicor…